

Amsellem-Ouazana 2005

Amsellem-Ouazana D, Younes P, Conquy S, Peyromaure M, Flam T, Debre B, *et al.* Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. *Eur Urol* 2005;**47**:582–6.

Babaian 2000

Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R, *et al.* A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. *J Urol* 2000;**163**:152–7.

Beyersdorff 2002

Beyersdorff D, Taupitz M, Winkelmann B, Fischer T, Lenk S, Loening SA, *et al.* Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. *Radiology* 2002;**224**:701–6.

Secondary publication

Winkelmann B, Beyersdorff D, Taupitz M, Deger S, Tuerk I, Loening SA. Value of high-resolution MR-imaging in patients with elevated PSA levels and negative TRUS-guided quadrant or sextant biopsy. *J Urol* 2001;**165**:317.

Bhatia 2007

Bhatia C, Phongkitkarun S, Booranapitaksonti D, Kochakarn W, Chaleumsanyakorn P. Diagnostic accuracy of MRI/MRSI for patients with persistently high PSA levels and negative TRUS-guided biopsy results. *J Med Assoc Thai* 2007;**90**:1391–9.

Calvo 2010

Calvo N, Henriquez L, I, Pujol F, Milia L, Pont A, Grio J, *et al.* Utility of magnetic resonance spectroscopy and guided biopsies in patients with previous negative biopsies and suspicious of prostate cancer. *Radiother Oncol* 2010;**96**(Suppl. 1):419.

Campodonico 2006

Campodonico F, Casarico A, Gavazzi L, Calcagno T, Capponi G, Canepa G, *et al.* Cancer detection with TRUS-guided 10-core biopsy of the prostate. an institutional assessment at the first, repeated and surgical specimen biopsy. *Arch Ital Urol Androl* 2006;**78**:39–43.

Cheikh 2009

Cheikh AB, Girouin N, Colombel M, Marechal JM, Gelet A, Bissery A, *et al.* Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. *Eur Radiol* 2009;**19**:770–8.

Chung 2010

Chung MS, Lee SH, Oh CK, Park SU, Rha KH, Oh YT, *et al.* MRI is important before repeat targeted biopsy in men with prior negative prostatic biopsy. *Eur Urol* 2010;**9**(Suppl. 3):501.

Cirillo 2008

Cirillo S, Petracchini M, Della MP, Gallo T, Tartaglia V, Vestita E, *et al.* Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours. *Clin Radiol* 2008;**63**:871–9.

Comet-Battle 2004

Comet-Battle J, Vilanova-Busquets J, Maroto-Genover A, Bucar-Terrades S, Lopez-Bonet E, Barcelo-Obregon J, et al. Targeting prostate cancer in the central gland with endorectal MRI and spectroscopy. *Eur Urol Suppl* 2004;**3**:36.

De La Rosette 2009

De La Rosette JJ, Wink MH, Mamoulakis C, Wondergem N, ten Kate FJ, Zwinderman K, et al. Optimizing prostate cancer detection: 8 versus 12-core biopsy protocol. *J Urol* 2009;**182**:1329–36.

Destefanis 2009

Destefanis P, Bosio A, De MC, Bisconti A, Cugiani A, Negro CLA, et al. Targeted needle re-biopsy of the prostate after combination of endorectal MRI (ENDOMRI) and magnetic resonance spectroscopy (MRS) in patients with atypical small acinar proliferation (ASAP). *Eur Urol Suppl* 2009;**8**:354.

Djavan 2001

Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? *J Urol* 2001;**166**:1679–83.

Engelhard 2006

Engelhard K, Hollenbach HP, Kiefer B, Winkel A, Goeb K, Engehausen D. Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device. *Eur Radiol* 2006;**16**:1237–43.

Eskicorapci 2007

Eskicorapci SY, Guliyev F, Islamoglu E, Ergen A, Ozen H. The effect of prior biopsy scheme on prostate cancer detection for repeat biopsy population: Results of the 14-core prostate biopsy technique. *Int Urol Nephrol* 2007;**39**:189–95.

Franiel 2011

Franiel T, Stephan C, Erbersdobler A, Dietz E, Maxeiner A, Hell N, et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding – multiparametric MR imaging for detection and biopsy planning. *Radiology* 2011;**259**:162–72.

Ghafoori 2010

Ghafoori M, Moradi M, Shakiba M, Hosseini K, Alavi M. Targeted TRUS-guided biopsy of prostate with the aid of MR spectroscopy in the patients with elevated PSA and negative previous systematic biopsy. *J Med Imag Radiat Oncol* 2010;**54**(Suppl. S1):A19.

Hambrock 2010

Hambrock T, Somford DM, Hoeks C, Bouwense SA, Huisman H, Yakar D, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. *J Urol* 2010;**183**:520–7.

Secondary publications

Hambrock T, Futterer JJ, Huisman HJ, Hulsbergen-van de Kaa C, Van Basten JP, Van Oort I, et al. Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility. *Invest Radiol* 2008;**43**:686–94.

Hambrock T, Somford D, Futterer J, Van Oort, I, Van Basten JP, Witjes A, et al. Value of 3 TESLA multi-modality directed MR-guided biopsy to detect prostate cancer in patients after at least two previous negative biopsies and elevated PSA. *J Urol* 2009;**181**(Suppl. 1):706.

Hambrock T, Somford DM, Futterer JJ, Hoeks CMA, Hulsbergen-Van De Kaa CA, Van Oort IM, *et al.* Value of 3 tesla multimodality MR-guided biopsy (MRGB) to detect prostate cancer in patients after at least two previous negative biopsies and an elevated PSA. *Eur Urol Suppl* 2009;**8**:195.

Hambrock T, Somford DM, Hoeks H. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. *J Vascul Intervent Radiol* 2010;**21**:764.

Hoeks 2012

Hoeks CMA, Schouten MG, Bomers JGR, Hoogendoorn SP, Hulsbergen-Van De Kaa CA, Hambrock T, *et al.* Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. *Eur Urol* 2012. doi.org/10.1016/j.eururo.2012.01.047

Keetch 1994

Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. *J Urol* 1994;**151**:1571–4.

Labanaris 2010

Labanaris AP, Engelhard K, Zugor V, Nützel R, Kühn R. Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate. *Prostate Cancer Prostat Dis* 2010;**13**:65–70.

Secondary publications

Labanaris AP, Engelhard K, Smiszek R, Nützel R, Kühn R. Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate. *J Urol* 2009;**181**(Suppl. 1):711–12.

Labanaris AP, Engelhard K, Nützel R, Smiszek R, Kühn R. Endorectal magnetic resonance imaging of the prostate. A useful tool in the detection of anterior prostate cancer. *J Urol* 2010;**183**(Suppl. 1):e719.

Lattouf 2007

Lattouf JB, Grubb RL III, Lee SJ, Bjurlin MA, Albert P, Singh AK, *et al.* Magnetic resonance imaging-directed transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer. *BJU Int* 2007;**99**:1041–6.

Lee 2011

Lee SH, Yeom CD, Park KK, Chung MS, Chung BH, Rha KH. Hard to detect prostate cancer diagnosed by targeted biopsy using combined T2 weighted and diffusion weighted magnetic resonance imaging. *J Urol* 2011;**185**(Suppl. 1):e849–50.

Lin 2008

Lin CC, Huang WJ, Wu LJ, Chang YH, Lin AT, Chen KK. Diagnosis of prostate cancer: repeated transrectal prostate biopsy or transurethral resection. *Journal of the Chinese Medical Association: JCMA* 2008;**71**:448–54.

Lopez-Corona 2003

Lopez-Corona E, Ohori M, Scardino PT, Reuter VE, Gonen M, Kattan MW. A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. *J Urol* 2003;**170**:1184–8.

Ozden 2005

Ozden E, Turgut AT, Yaman O, Gulpinar O, Baltaci S. Follow-up of the transrectal ultrasonographic features of the prostate after biopsy: does any ultrasonographically detectable lesion form secondary to the first biopsy? *J Ultrasound Med* 2005;**24**:1659–63.

Panebianco 2011

Panebianco V, Sciarra A, De Berardinis E, Busetto GM, Lisi D, Buonocore V, *et al.* PCA3 urinary test versus 1H-MRSI and DCEMR in the detection of prostate cancer foci in patients with biochemical alterations. *Anticancer Res* 2011;**31**:1399–405.

Secondary publications

Busetto GM, Panebianco V, Sciarra A, De Berardinis E, Tommaso B, Danilo L, *et al.* PCA3 urinary test versus 3T 1H-MRS and DCE-MRI in the detection of prostate cancer foci in patients with biochemical alterations. *Anticancer Res* 2011;**31**:1845.

Di Silverio F, Salciccia S, Busetto GM, Panebianco V, Sciarra A, Lisi D, *et al.* Is prostate biopsy still necessary? *Anticancer Res* 2011;**31**:1929–30.

Park 2008

Park BK, Lee HM, Kim CK, Choi HY, Park JW. Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen level using diffusion-weighted imaging at three Tesla before rebiopsy. *Invest Radiol* 2008;**43**:789–93.

Pepe 2010

Pepe P, Candiano G, Fraggetta F, Galia A, Grasso G, Aragona F. Is transition zone sampling at repeated saturation prostate biopsy still useful? *Urol Int* 2010;**85**:324–7.

Perrotti 2002

Perrotti M, Ankem MK, Weiss RE, Epstein R, Decarvalho VS, Kattan M, *et al.* Endorectal MRI: Adjunct to repeat biopsy in prostate cancer detection. The smart biopsy. *J Urol* 2002;**167**:387.

Secondary publication

Perrotti M, Shurtleff B, Rabbani F, Epstein R, Kennedy E, Weiss R, *et al.* Endorectal MRI-prospective localization of prostate tumor foci in men with prior negative prostatic biopsies: 60 Consecutive cases. *J Urol* 2000;**163**:281.

Philip 2006

Philip J, Hanchanale V, Foster CS, Javle P. Importance of peripheral biopsies in maximising the detection of early prostate cancer in repeat 12-core biopsy protocols. *BJU Int* 2006;**98**:559–562.

Pinsky 2007

Pinsky PF, Crawford ED, Kramer BS, Andriole GL, Gelmann EP, Grubb R, *et al.* Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. *BJU Int* 2007;**99**:775–9.

Portalez 2010

Portalez D, Rollin G, Leandri P, Elman B, Mouly P, Jonca F, *et al.* Prospective comparison of T2w-MRI and dynamic-contrast-enhanced MRI, 3D-MR spectroscopic imaging or diffusion-weighted MRI in repeat TRUS-guided biopsies. *Eur Radiol* 2010;**20**:2781–90.

Secondary publication

Portalez D, Rollin G, Leandri P, Elman B, Mouly P, Jonca F, *et al.* Prospective comparison of T2W-MRI and dynamic-contrast-enhanced MRI, 3D-MR spectroscopic imaging or diffusion-weighted MRI in repeat TRUS-guided biopsies. *Eur Urol Suppl* 2010;**9**:197–8.

Prando 2005

Prando A, Kurhanewicz J, Borges AP, Oliveira EM Jr, Figueiredo E. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. *Radiology* 2005;**236**:903–10.

Quinlan 2009

Quinlan MR, Casey RG, Flynn R, Grainger R, McDermott TE, Thornhill JA. A review of repeat prostate biopsies and the influence of technique on cancer detection: our experience. *Ir J Med Sci* 2009;**178**:287–90.

Rahman 2003

Rahman NU, Franks JH, Suhta A, Kurhanewicz J, Shinohara K. Utility of MRI/MRS in predicting prostate cancer for patients with multiple prior negative biopsies. *J Urol* 2003;**169**:495.

Roehl 2002

Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. *J Urol* 2002;**167**:2435–9.

Roethke 2012

Roethke M, Anastasiadis AG, Lichy M, Werner M, Wagner P, Kruck S, *et al.* MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. *World J Urol* 2012;**30**:213–18.

Sciarra 2010

Sciarra A, Panebianco V, Ciccariello M, Saliccia S, Cattarino S, Lisi D, *et al.* Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. *Clin Cancer Res* 2010;**16**:1875–83.

Secondary publications

Panebianco V, Sciarra A, Ciccariello M, Lisi D, Bernardo S, Cattarino S, *et al.* Role of magnetic resonance spectroscopic imaging ([¹H]MRSI) and dynamic contrast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in patients with negative biopsy and high levels of prostate-specific antigen (PSA). *Radiol Med* 2010;**115**:1314–29.

Sciarra A, Panebianco V, Saliccia S, Gentilucci A, Parente U, Alfarone A, *et al.* Value of magnetic resonance spectroscopy imaging (MRSI) and dynamic contrast-enhanced imaging MR (DCEMR) for the detection of prostate adenocarcinoma foci in men with prior negative prostate biopsy and elevated prostate specific antigen (PSA) levels. *Eur Urol Suppl* 2010;**9**:231.

Sciarra A, Panebianco V, Saliccia S, Alessandro G, Ulderico P, Andrea A, *et al.* Value of magnetic resonance spectroscopy imaging (MRSI) and dynamic contrast-enhanced imaging MR (DCEMR) for the detection of prostate adenocarcinoma foci in men with prior negative prostate biopsy and elevated prostate specific antigen (PSA) levels. *J Urol* 2010;**183**(Suppl. 1):e719.

Testa 2010

Testa C, Schiavina R, Lodi R, Salizzoni E, Tonon C, D'Errico A, *et al.* Accuracy of MRI/MRSI-based transrectal ultrasound biopsy in peripheral and transition zones of the prostate gland in patients with prior negative biopsy. *NMR Biomed* 2010;**23**:1017–26.

Ukimura 1997

Ukimura O, Durrani O, Joseph BR. Role of PSA and its indices in determining the need for repeat prostate biopsies. *Urology* 1997;**50**:66–72.

Valentini 2010

Valentini AL, Pinto F, Totaro A, Sacco E, Volpe A, Racioppi M, *et al.* Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging and prostate cancer detection: preliminary results. *Anticancer Res* 2010;**30**:1500.

Wefer 2000

Wefer AE, Hricak H, Okuno W, Carroll P, Kurhanewicz J. Magnetic resonance imaging and spectroscopy: targeted prostate biopsy. *J Urol* 2000;**163**:280–1.

Wetter 2005

Wetter A, Hubner F, Lehnert T, Fließbach K, Vorbuchner M, Roell S, *et al.* Three-dimensional 1H-magnetic resonance spectroscopy of the prostate in clinical practice: technique and results in patients with elevated prostate-specific antigen and negative or no previous prostate biopsies. *Eur Radiol* 2005;**15**:645–52.

Yakar 2011

Yakar D, Schouten MG, Bosboom DG, Barentsz JO, Scheenen TW, Futterer JJ. Feasibility of a pneumatically actuated MR-compatible robot for transrectal prostate biopsy guidance. *Radiology* 2011;**260**:241–7.

Yanke 2006

Yanke BV, Salzhauer EW, Colon I. Is race a positive predictor of cancer on repeat prostate biopsy? *J Urol* 2006;**176**:1114–17.

Yao 2009

Yao DF, DeWolf WC, Sanda MG, Bloch BN, Genega EM, Berry AM, *et al.* Increased positive yield of clinically significant prostate cancer with MRI prompted biopsies. *J Urol* 2009;**181**(Suppl. 1):782–3.

Younes 2001

Younes P, Zerbib M, Saighi D, Conquy S, Thiounn N, Flam T, *et al.* Interest of endorectal MRI for patients with a high risk of prostate cancer but negative sextant biopsies. *Eur Urol* 2001;**39**:148.

Yuen 2004

Yuen JS, Lau WK, Ng LG, Tan PH, Khin LW, Cheng CW. Clinical, biochemical and pathological features of initial and repeat transrectal ultrasonography prostate biopsy positive patients. *Int J Urol* 2004;**11**:225–31.

Yuen 2004

Yuen JS, Thng CH, Tan PH, Khin LW, Phee SJ, Xiao D, *et al.* Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. *J Urol* 2004;**171**:1482–6.

Zackrisson 2004

Zackrisson B, Aus G, Bergdahl S, Lilja H, Lodding P, Pihl CG, *et al.* The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable. *J Urol* 2004;**171**:1500–3.